MDR 2017/745 — what foreign MedTech manufacturers need to know about the German market
The core obligations under the EU MDR — from technical documentation through BfArM to vigilance. A practical guide with a checklist for foreign manufacturers in the German hospital market.
The EU Medical Device Regulation 2017/745 (MDR) has been fully in force since May 2021. For foreign manufacturers who want to enter the German hospital market, it is less a technical detail than a structural barrier to entry — and at the same time an opportunity to differentiate. This guide sets out what the MDR means in practice for your market entry: which obligations apply to you as a non-EU manufacturer, how the interplay with BfArM and Eudamed works, where the most common mistakes arise — and why the compliance question in Germany is at heart a listing question.
Why the MDR is a listing problem in Germany
Most foreign manufacturers understand the MDR as a pure CE mark topic: once the conformity assessment is done, the product is marketable. In Germany that is not enough.
The reality of German hospital procurement is structured differently. Procurement departments in large hospitals and Einkaufsgemeinschaften check more than CE conformity before any listing. They check the full MDR pipeline:
- BfArM registration (BfArM is the German federal institute for drugs and medical devices) with a named German responsible person
- Eudamed publication of the UDI and technical master data
- Established vigilance processes — not just on paper
- Documented post-market surveillance across several quarters
- A clear chain of responsibility between manufacturer, EU Authorized Representative, German sales organization and PRRC
A CE mark alone means you have just reached the minimum requirement in Germany. It is not listing readiness.
In practice that means you can be fully compliant in regulatory terms and still not be listed in German hospitals, because the cleanliness of your pipeline does not convince from a procurement perspective.
The obligations of foreign manufacturers at a glance
As a manufacturer based outside the EU, you need a set of organizational and documentary arrangements before your product can enter the German market on a regulatory footing that holds.
EU Authorized Representative (Art. 11 MDR)
An authorized representative established in the EU is mandatory. They act on the manufacturer’s behalf towards authorities, keep the technical documentation available and share responsibility for vigilance and recalls. In MEX mandates we generally take on the EU Authorized Representative function through the German client GmbH.
Person Responsible for Regulatory Compliance (PRRC, Art. 15 MDR)
At least one person with qualified regulatory responsibility must be appointed. They oversee conformity, the technical documentation, post-market surveillance and vigilance reporting. The function can be filled internally or externally — MEX provides PRRC functions for client GmbHs.
Technical documentation (Annexes II and III)
The complete technical documentation must be available, auditable and current. Annex II covers the product itself (description, specifications, conformity assessment, risk analysis, clinical evaluation). Annex III covers the PMS documentation (PMS plan, PSUR safety reports, PMCF plan).
UDI assignment and Eudamed registration
Every MDR product needs a UDI (Unique Device Identifier). Registration takes place in Eudamed, the central EU database for medical devices. Eudamed has been becoming mandatory in stages since 2024 and is, in practice, decisive for visibility with German hospitals.
Post-market surveillance and PSUR
A PMS plan is mandatory, and periodic safety update reports (PSURs) follow from it — every two years for Class IIa products, annually for Class IIb and III. Hospitals increasingly ask for these reports directly.
Vigilance pipeline
Serious incidents and field safety corrective actions must be reported to BfArM. The chain from user (hospital) to sales organization to manufacturer to BfArM has to be in place before the first listing, not after the first incident.
How BfArM and Eudamed interact
The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the German competent authority for medical devices. Even though Eudamed is centralized at European level, German market access runs in practice through BfArM acceptance and national reporting obligations.
For your pipeline that means:
- Eudamed supplies the UDI master data and makes your products findable across the EU.
- BfArM is your national point of contact for vigilance reports, inspection cases and market surveillance.
- German Einkaufsgemeinschaften and large hospital groups frequently check both sources — Eudamed for conformity, BfArM for current vigilance and recall status.
A German contact address with a German phone number, German instructions for use and a German labeling set are not nice-to-haves in practice. They are a precondition for listing.
The most common mistakes — and how to avoid them
From 27 years of MEX mandates we know the recurring stumbling blocks. They are rarely deep regulatory issues; they are almost always organizational.
Appointing the PRRC too late
The PRRC function is often only addressed when the notified body asks for it. The consequence: the CE mark slips by weeks and listing preparation in Germany slips by months. The fix: appoint the PRRC in parallel with the first build of the technical documentation.
Incomplete technical documentation in hospital communication
Hospital procurement increasingly asks for extracts from the technical documentation — usually the clinical evaluation, the PMS plan and the latest PSUR. If you cannot deliver these within 48 hours, you will be assessed as organizationally immature in the listing decision.
Missing German translations
The MDR requires instructions for use, labels and safety-relevant information in the language of the member state. In practice, German hospitals do not accept English IFUs without an accompanying translation. Within the client mandate, MEX handles translation both regulatorily and linguistically.
Unclear vigilance responsibilities
Who reports what, when, and to whom? If the vigilance chain between manufacturer, EU Authorized Representative, German sales organization and PRRC is not documented before the first sale, incidents produce delays that turn into major findings in audits.
Mistaking listing readiness for the CE mark
What all of these mistakes have in common is not regulatory depth but the organizational interface: who is responsible for what once the product has arrived at the hospital? Who responds, and within what time? Who is the German point of contact for procurement?
The MEX pipeline for foreign manufacturers
In MEX mandates we build the MDR pipeline together with hospital sales and logistics via DSW Logistik, inside the same GmbH structure. Specifically:
- The client GmbH acts as EU Authorized Representative.
- MEX provides the PRRC function.
- Technical documentation is maintained bilingually (EN/DE).
- Vigilance runs through the German GmbH; the field force and DSW Logistik are integrated into the reporting chain.
- We produce PMS and PSUR annually; extracts go automatically to the most important Einkaufsgemeinschaften.
This integrated pipeline is what separates MDR compliance from listing readiness in Germany — and what conventional distributors and marketing agencies structurally cannot deliver.
Steps to listing readiness — the MEX checklist
- Finalize the product’s MDR classification (Class I/IIa/IIb/III) and derive the conformity assessment route.
- Appoint an EU Authorized Representative — in MEX mandates, through the German client GmbH.
- Fill the PRRC role — internally at the manufacturer or at MEX.
- Raise the technical documentation to MDR standard (Annexes II and III) and maintain it bilingually.
- Assign the UDI and register in Eudamed.
- Set out the PMS plan and vigilance pipeline in writing — including the German reporting chain.
- Produce German IFUs, labels and safety information.
- Communicate with BfArM — proactively, before the first hospital asks.
- Prepare a first PSUR or vigilance demonstration before the first listing conversation.
- Initiate hospital listing — with the complete documentation set available from the first meeting.
How this works operationally with MEX
We typically start with an MDR gap analysis over four to six weeks: what is already in place, what is missing, and in what order does it make sense to close the gaps? That produces a pipeline roadmap, which we then execute through Module 1 (GmbH infrastructure), Module 2 (MDR compliance) and Module 4 (hospital sales and listings).
With clean preparatory work, time to first listing runs between 8 and 16 weeks from the start of the mandate — faster if the technical documentation from the home market is already MDR-ready, slower if UDI assignment or clinical evaluation still have to be caught up.
Frequently asked questions
Do we need our own German GmbH, or is an EU Authorized Representative enough?
For MDR compliance, an EU Authorized Representative anywhere in the EU is enough. For German hospital listings, a German address with German points of contact and a German vigilance chain is a practical precondition. MEX combines both in the client GmbH.
Who takes on PRRC responsibility in MEX mandates?
We offer the PRRC function as part of our regulatory layer. Alternatively you fill it internally; we coordinate in either configuration.
How quickly are first hospital listings realistic?
With a clean MDR pipeline and a suitable product category, we see first listings 8 to 16 weeks after the start of the mandate. The precondition is a working field force (Module 4) running in parallel with the compliance layer.
What role does BfArM play compared with Eudamed?
Eudamed is the EU-central database for master data and vigilance publications. BfArM is the German competent authority for national reporting, inspections and market surveillance. Both matter for German market entry; in practice, BfArM is the source hospital procurement cites more quickly.
What happens if we do not continue after a pilot?
In MEX mandates a clean exit is an explicit part of the contract structure. The MDR pipeline and all listings remain the property of the client and its German company; the service agreements with MEX and DSW Logistik are terminated. Compared with your own subsidiary, the sunk cost burden stays considerably lower.